菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button ps_marketing@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

WuXian Transient™


The WuXian Transient™ platform is built on CHO cells, the industry standard for therapeutic protein production, renowned for its high growth rates, high titers, and ability to generate antibodies with essential post-translational modifications (PTMs).

 

Derived from the robust CHO-K1 cells, the WuXian Transient™ expression platform enables high-throughput production of premium-quality proteins and antibodies. Supporting scales from small pilot studies to gram-level yields, this platform significantly accelerates the pace of therapeutic drug development.

WuXian Transient™: CHO system derived from CHO-K1 cells that stands out for its high-titer expression capabilities, ensuring optimal protein yield in a shorter time frame.

The timeline below showcases significant titer improvement from the initial launch of WuXian Transient™ 1.0 in 2014, which achieved 0.15 g/L over 10 days, to the outstanding performance of WT 3.0 in 2024, reaching a titer of 2.6 g/L within just a 7 days. These milestones highlight our commitment to innovation, driven by advancements in bioinformatics-guided codon optimization and gradually improved transfection and cultivation conditions over years. Together, these enhancements have substantially improved our productivity and efficiency in antibody and protein production.

The timeline shows titer innovation from WuXian Transient™ 1.0 (0.15 g/L in 10 days, 2014) to WT 3.0 (2.6 g/L in 7 days, 2024).

The WuXian Transient™ platform is further distinguished by its exceptional scalability, enabling seamless scale-up while maintaining consistent, high-quality outputs. This ensures sufficient material for downstream applications, including later-stage characterization testing and a smooth transition into CMC development.

Case Study #1: High-Titer Production Across Diverse Antibody Formats Using WuXian Transient™ Platform

This case study highlights the ultra-high-titer CHO transient expression of antibodies and proteins across various formats, including control antibodies, vanilla antibodies, bispecific antibodies (bsAbs), and fusion proteins.

Case study on ultra-high-titer CHO transient expression of antibodies and proteins using the WuXian Transient™ platform, covering control antibodies, vanilla antibodies, bispecific antibodies (bsAbs), and fusion proteins.

Figure A: The control antibody demonstrated a significant titer improvement, reaching 2.63 g/L on Day 7. The platform also effectively expressed a range of project molecules, achieving titers of 1.58 g/L for vanilla antibodies, 1.49 g/L for bsAbs, and 1.40 g/L for fusion proteins.

Case Study #2: WuXian Transient™ Platform Achieves Gram-Scale mAb Production in 3 Weeks

This case study demonstrates the rapid, high-titer production of monoclonal antibodies (mAbs) using the WuXian Transient™ platform, achieving gram-level yield within a 3-week timeline.

Case study demonstrating the rapid, high-yield production of monoclonal antibodies (mAbs) using the WuXian Transient™ platform, achieving gram-scale quantities within 3 weeks.

Figure A: A murine IgG2a (mIgG2a) antibody was expressed in a 10 L culture using the WuXian Transient™ system and purified on Day 7 through AC-CEX purification. The process yielded approximately 12 grams of the target antibody, with subsequent analysis by SEC-HPLC confirming a final product purity of 98.8%.

 

Your Project. Our Expertise.